Last reviewed · How we verify
aflibercept + FOLFIRI
Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.
Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan. Used for Metastatic colorectal cancer (in combination with FOLFIRI), Second-line treatment of metastatic colorectal cancer.
At a glance
| Generic name | aflibercept + FOLFIRI |
|---|---|
| Also known as | aflibercept, FOLFIRI |
| Sponsor | CR-CSSS Champlain-Charles-Le Moyne |
| Drug class | VEGF inhibitor (fusion protein) + chemotherapy combination |
| Target | VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Aflibercept is a VEGF trap that sequesters vascular endothelial growth factor, preventing new blood vessel formation that tumors depend on for growth. FOLFIRI is a combination chemotherapy regimen (5-fluorouracil, leucovorin, and irinotecan) that damages DNA and inhibits topoisomerase I. Together, they provide dual anti-angiogenic and cytotoxic activity against colorectal cancer.
Approved indications
- Metastatic colorectal cancer (in combination with FOLFIRI)
- Second-line treatment of metastatic colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Fatigue
- Nausea
- Abdominal pain
- Hypertension
- Proteinuria
- Hemorrhage
Key clinical trials
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (PHASE2)
- Resection Observatory
- ZETA : Prospective Observational Study
- TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (PHASE3)
- Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (PHASE2)
- Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (PHASE2)
- Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aflibercept + FOLFIRI CI brief — competitive landscape report
- aflibercept + FOLFIRI updates RSS · CI watch RSS
- CR-CSSS Champlain-Charles-Le Moyne portfolio CI